Erasca, Inc.
ERAS
Classement en actions
#3575
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Prix de l'action
$13.56
Capitalisation boursière
$4.74B
Changement (1 jour)
1.24%
Changement (1 an)
460.17%
Pays
US
Échange Erasca, Inc. (ERAS)
Catégorie
Healthcare
EPS pour Erasca, Inc. (ERAS)
EPS au June 2026 TTM : $-0.95
Selon les derniers rapports financiers et le cours de l'action de Erasca, Inc., l’EPS actuel de la société (TTM) est de $-0.95. À la fin de 2023, la société avait un EPS de $-0.83 une diminution par rapport à celui de 2022, qui était de $-1.99.
Historique de l'EPS de Erasca, Inc. de 2019 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-0.95 | 37.68% |
| 2024 | $-0.69 | -16.87% |
| 2023 | $-0.83 | -58.29% |
| 2022 | $-1.99 | 93.20% |
| 2021 | $-1.03 | 21.18% |
| 2020 | $-0.85 | 750.00% |
| 2019 | $-0.10 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -1,923.16% |
US
|
|
| $-7.98 | 740.00% |
US
|
|
| $-5.29 | 456.84% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,020.00% |
NL
|
